Skip to main content
. Author manuscript; available in PMC: 2023 Apr 22.
Published in final edited form as: Mol Cell. 2023 Mar 15:S1097-2765(23)00153-3. doi: 10.1016/j.molcel.2023.02.026

Figure 7. mSWI/SNF targeting improves T cell-based cancer immunotherapy approaches.

Figure 7.

(A) FACS plots depicting PD1/TIM3 populations in DMSO, ACBI1, AU-15330, CMP14, and FHT-1015 conditions (100 nM), at day 9, for one human CD4+ T cell donor (donor 8).

(B) FACS plot depicting the profiling of CD39 in human CD4+ T cells treated with DMSO, ACBI1, AU-15330, CMP14, or FHT-1015 (100 nM), at day 9.

(C) Bar graph depicting human CD4+ T cell number upon treatment with DMSO, ACBI1, AU-15330, CMP14, or FHT-1015 (100 nM). Error bars represent the mean ± SD of 3 technical replicates of one donor.

(D) Schematic for CD19-CAR-T cell generation, stimulation, and treatments.

(E) FACS plots depicting CD19-CAR-T-GFP cells identification and PD1/TIM3 populations, in cells treated with ACBI1 or AU-15330 (donors 9 and 10).

(F) FACS histograms of LAG-3 and CD39 expression in CAR-T cells treated with DMSO, ACBI1, or AU-15330.

(G) Bar graphs depicting CAR-T cell number upon treatment with DMSO, ACBI1, or AU-15330 (100 nM). Error bars represent the mean for each donor.

(H) Bar graphs depicting cell number upon treatment with ACBI1, AU-15330, or FHT-1015 (all 100 nM) at day 3 onward or at day 3 with treatment washout at day 9. Error bars represent mean ± SD of 3 technical replicates of one donor.

(I) In vivo B16 melanoma tumor growth curves in mice injected with DMSO or FHT-1015-treated CD8+ OT-1 T cells. Two-way ANOVA generated p value for comparison between the two groups’ means at day 19: p < 0.05.

See also Figure S7.